Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model

Circulation Research

Volumn 106, Issue 9, 2010, Pages 1449-1458

  Ramasamy, Ravichandran ^a   Goldberg, Ira J ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

Atherosclerosis; Diabetes; Fructose; Macrovascular disease

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; DIACYLGLYCEROL; EPALRESTAT; PLACEBO; POLYOL; TOLRESTAT; ZOPOLRESTAT;

ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DRUG MECHANISM; ENZYME ACTIVITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GLYCOLYSIS; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENAL PROTECTION; REVIEW; SPECIES DIFFERENCE; TISSUE SPECIFICITY;

ALDEHYDE REDUCTASE; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; HUMANS;

EID: 77952403264     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.109.213447     Document Type: Review

References (138)

1. Hsueh W, Abel ED, Breslow JL, Maeda N, Davis RC, Fisher EA, Dansky H, McClain DA, McIndoe R, Wassef MK, Rabadan-Diehl C, Goldberg IJ. Recipes for creating animal models of diabetic cardiovascular disease. Circ Res. 2007;100:1415-1427.
2. Holden PR, Tugwood JD. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J Mol Endo-crinol. 1999;22:1-8.
3. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99-S112.
4. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem. 2003;278:34268-34276.
5. Breyer MD, Bottinger E, Brosius FC, Coffman TM, Fogo A, Harris RC, Heilig CW, Sharma K. Diabetic nephropathy: of mice and men. Adv Chronic Kidney Dis. 2005;12:128-145.
6. McReynolds MR, Taylor-Garcia KM, Greer KA, Hoying JB, Brooks HL. Renal medullary gene expression in aquaporin-1 null mice. Am J Physiol Renal Physiol. 2005;288:F315-F321.
7. Moeckel GW, Zhang L, Chen X, Rossini M, Zent R, Pozzi A. Role of integrin alpha1beta1 in the regulation of renal medullary osmolyte concentration. Am J Physiol Renal Physiol. 2006;290:F223-F231.
8. Wendt T, Bucciarelli L, Qu W, Lu Y, Yan SF, Stern DM, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep. 2002;4:228-237.
9. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48:1-9.
10. Brownlee M. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic complications. In: Rifkin H, Porte D Jr, eds. Ellenberg and Rifkin's Diabetes Mellitus. Stamford, Conn: Appleton & Lange; 1997:229-256.
11. Cohen MP. Diabetes and Protein Glycosylation: Measurement and Biologic Relevance. New York: Springer-Verlag; 1986.
12. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000;1498:99-111.
13. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab. 2001;280: E685-E694.
14. Ramasamy R, Hwang YC, Whang J, Bergmann SR. Protection of ischemic hearts by high glucose is mediated, in part, by GLUT-4. Am J Physiol Heart Circ Physiol. 2001;281:H290-H297.
15. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99:578-588.
16. Heilig CW, Brosius FC, III, Henry DN. Glucose transporters of the glomerulus and the implications for diabetic nephropathy. Kidney Int Suppl. 1997;60:S91-S99.
17. Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol. 2002;50:325-392.
18. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405-412.
19. Williamson JR, Kilo C, Ido Y. The role of cytosolic reductive stress in oxidant formation and diabetic complications. Diabetes Res Clin Pract. 1999;45:81-82.
20. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.
21. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859-866.
22. Tilton RG. Diabetic vascular dysfunction: links to glucose-induced reductive stress and VEGF. Microsc Res Tech. 2002;57:390-407.
23. Ishii H, Tada H, Isogai S. An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-beta and protein kinase C activity in cultured mesangial cells. Diabetologia. 1998;41: 362-364.
24. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787-790.
25. Trueblood N, Ramasamy R. Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts. Am J Physiol. 1998;275:H75-H83.
26. Jez JM, Penning TM. The aldo-keto reductase (AKR) superfamily: an update. Chem Biol Interact. 2001;130-132:499-525.
27. Petrash JM, Tarle I, Wilson DK, Quiocho FA. Aldose reductase catalysis and crystallography. Insights from recent advances in enzyme structure and function. Diabetes. 1994;43:955-959.
28. Grimshaw CE, Bohren KM, Lai CJ, Gabbay KH. Human aldose reductase: rate constants for a mechanism including interconversion of ternary complexes by recombinant wild-type enzyme. Biochemistry. 1995;34:14356-14365.
29. Clements RS Jr, Weaver JP, Winegrad AI. The distribution of polyol: NADP oxidoreductase in mammalian tissues. Biochem Biophys Res Commun. 1969;37:347-353.
30. Ludvigson MA, Sorenson RL. Immunohistochemical localization of aldose reductase. II. Rat eye and kidney. Diabetes. 1980;29:450-459.
31. Rondeau JM, Tete-Favier F, Podjarny A, Reymann JM, Barth P, Biellmann JF, Moras D. Novel NADPH-binding domain revealed by the crystal structure of aldose reductase. Nature. 1992;355:469-472.
32. Hers HG. [Aldose reductase.]. Biochim Biophys Acta. 1960;37: 120-126.
33. Srivastava S, Chandra A, Bhatnagar A, Srivastava SK, Ansari NH. Lipid peroxidation product, 4-hydroxynonenal and its conjugate with GSH are excellent substrates of bovine lens aldose reductase. Biochem Biophys Res Commun. 1995;217:741-746.
34. Srivastava S, Watowich SJ, Petrash JM, Srivastava SK, Bhatnagar A. Structural and kinetic determinants of aldehyde reduction by aldose reductase. Biochemistry. 1999;38:42-54.
35. Vander Jagt DL, Kolb NS, Vander Jagt TJ, Chino J, Martinez FJ, Hunsaker LA, Royer RE. Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate. Biochim Biophys Acta. 1995;1249:117-126.
36. Crosas B, Hyndman DJ, Gallego O, Martras S, Pares X, Flynn TG, Farres J. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem J. 2003;373:973-979.
37. Inagaki K, Miwa I, Okuda J. Affinity purification and glucose specificity of aldose reductase from bovine lens. Arch Biochem Biophys. 1982;216: 337-344.
38. Grimshaw CE. Direct measurement of the rate of ring opening of D-glucose by enzyme-catalyzed reduction. Carbohydr Res. 1986;148: 345-348.
39. Petrash JM, Harter TM, Devine CS, Olins PO, Bhatnagar A, Liu S, Srivastava SK. Involvement of cysteine residues in catalysis and inhibition of human aldose reductase. Site-directed mutagenesis of Cys-80,-298, and-303. J Biol Chem. 1992;267:24833-24840.
40. Srivastava S, Dixit BL, Ramana KV, Chandra A, Chandra D, Zacarias A, Petrash JM, Bhatnagar A, Srivastava SK. Structural and kinetic modifications of aldose reductase by S-nitrosothiols. Biochem J. 2001; 358:111-118.
41. Hwang YC, Sato S, Tsai JY, Yan S, Bakr S, Zhang H, Oates PJ, Ramasamy R. Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J. 2002;16:243-245.
42. Chandra D, Jackson EB, Ramana KV, Kelley R, Srivastava SK, Bhatnagar A. Nitric oxide prevents aldose reductase activation and sorbitol accumulation during diabetes. Diabetes. 2002;51:3095-3101.
43. Robinson B, Hunsaker LA, Stangebye LA, Vander Jagt DL. Aldose and aldehyde reductases from human kidney cortex and medulla. Biochim Biophys Acta. 1993;1203:260-266.
44. Graham A, Heath P, Morten JE, Markham AF. The human aldose reductase gene maps to chromosome region 7q35. Hum Genet. 1991; 86:509-514.
45. Chung S, LaMendola J. Cloning and sequence determination of human placental aldose reductase gene. J Biol Chem. 1989;264:14775-14777.
46. Wang K, Bohren KM, Gabbay KH. Characterization of the human aldose reductase gene promoter. J Biol Chem. 1993;268:16052-16058.
47. Ko BC, Ruepp B, Bohren KM, Gabbay KH, Chung SS. Identification and characterization of multiple osmotic response sequences in the human aldose reductase gene. J Biol Chem. 1997;272:16431-16437.
48. Bateman JB, Kojis T, Heinzmann C, Klisak I, Diep A, Carper D, Nishimura C, Mohandas T, Sparkes RS. Mapping of aldose reductase gene sequences to human chromosomes 1, 3, 7, 9, 11, and 13. Genomics. 1993;17:560-565.
49. Oates PJ, Mylari BL. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin Investig Drugs. 1999;8: 2095-2119.
50. Ko BC, Lam KS, Wat NM, Chung SS. An (A-C)n dinucleotide repeat polymorphic marker at the 5' end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes. 1995;44:727-732.
51. Kao YL, Donaghue K, Chan A, Knight J, Silink M. A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes. Diabetes. 1999;48:1338-1340.
52. Lee SC, Wang Y, Ko GT, Critchley JA, Ng MC, Tong PC, Cockram CS, Chan JC. Association of retinopathy with a microsatellite at 5' end of the aldose reductase gene in Chinese patients with late-onset Type 2 diabetes. Ophthalmic Genet. 2001;22:63-67.
53. Kao YL, Donaghue K, Chan A, Knight J, Silink M. An aldose reductase intragenic polymorphism associated with diabetic retinopathy. Diabetes Res Clin Pract. 1999;46:155-160.
54. Demaine A, Cross D, Millward A. Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus. Invest Ophthalmol Vis Sci. 2000;41:4064-4068.
55. Moczulski DK, Scott L, Antonellis A, Rogus JJ, Rich SS, Warram JH, Krolewski AS. Aldose reductase gene polymorphisms and susceptibility to diabetic nephropathy in Type 1 diabetes mellitus. Diabet Med. 2000; 17:111-118.
56. Shah VO, Scavini M, Nikolic J, Sun Y, Vai S, Griffith JK, Dorin RI, Stidley C, Yacoub M, Vander Jagt DL, Eaton RP, Zager PG. Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy. J Clin Endocrinol Metab. 1998; 83:2886-2891.
57. Heesom AE, Hibberd ML, Millward A, Demaine AG. Polymorphism in the 5'-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Diabetes. 1997; 46:287-291.
58. Heesom AE, Millward A, Demaine AG. Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5' end of the aldose reductase gene. J Neurol Neurosurg Psychiatry. 1998;64:213-216.
59. So WY, Wang Y, Ng MC, Yang X, Ma RC, Lam V, Kong AP, Tong PC, Chan JC. Aldose reductase genotypes and cardiorenal complications: an 8-year prospective analysis of 1,074 type 2 diabetic patients. Diabetes Care. 2008;31:2148-2153.
60. Watarai A, Nakashima E, Hamada Y, Watanabe G, Naruse K, Miwa K, Kobayashi Y, Kamiya H, Nakae M, Hamajima N, Sekido Y, Niwa T, Oiso Y, Nakamura J. Aldose reductase gene is associated with diabetic macroangiopathy in Japanese type 2 diabetic patients. Diabet Med. 2006;23:894-899.
61. Markus HB, Raducha M, Harris H. Tissue distribution of mammalian aldose reductase and related enzymes. Biochem Med. 1983;29:31-45.
62. Tanimoto T, Maekawa K, Okada S, Yabe-Nishimura C. Clinical analysis of aldose reductase for differential diagnosis of the pathogenesis of diabetic complication. Analytica Chimica Acta. 1998;365:285-292.
63. Hwang YC, Kaneko M, Bakr S, Liao H, Lu Y, Lewis ER, Yan S, Ii S, Itakura M, Rui L, Skopicki H, Homma S, Schmidt AM, Oates PJ, Szabolcs M, Ramasamy R. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J. 2004;18:1192-1199. (Pubitemid 39006881)
64. Srivastava S, Vladykovskaya E, Barski OA, Spite M, Kaiserova K, Petrash JM, Chung SS, Hunt G, Dawn B, Bhatnagar A. Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice. Circ Res. 2009;105:793-802.
65. Hers HG. [The mechanism of the transformation of glucose in fructose in the seminal vesicles.]. Biochim Biophys Acta. 1956;22:202-203.
66. Oates PJ, Goddu JK. A sorbitol gradient in rat inner medulla. Kidney Int. 1987;31:448.
67. Burg MB, Kwon ED, Kultz D. Regulation of gene expression by hyper-tonicity. Annu Rev Physiol. 1997;59:437-455.
68. Burg MB. Coordinate regulation of organic osmolytes in renal cells. Kidney Int. 1996;49:1684-1685.
69. Srivastava SK, Ansari NH, Brown JH, Petrash JM. Formation of sorbitol 6-phosphate by bovine and human lens aldose reductase, sorbitol dehy-drogenase and sorbitol kinase. Biochim Biophys Acta. 1982;717: 210-214.
70. Szwergold BS, Kappler F, Brown TR, Pfeffer P, Osman SF. Identification of D-sorbitol 3-phosphate in the normal and diabetic mammalian lens. J Biol Chem. 1989;264:9278-9282.
71. Szwergold BS, Kappler F, Brown TR. Identification of fructose 3-phosphate in the lens of diabetic rats. Science. 1990;247:451-454.
72. Petrash JM, Harter TM, Murdock GL. A potential role for aldose reductase in steroid metabolism. Adv Exp Med Biol. 1997;414:465-473.
73. Kawamura M, Kopin IJ, Kador PF, Sato S, Tjurmina O, Eisenhofer G. Effects of aldehyde/aldose reductase inhibition on neuronal metabolism of norepinephrine. J Auton Nerv Syst. 1997;66:145-148.
74. Grimshaw CE. Aldose reductase: model for a new paradigm of enzymic perfection in detoxification catalysts. Biochemistry. 1992;31: 10139-10145.
75. Dixit BL, Balendiran GK, Watowich SJ, Srivastava S, Ramana KV, Petrash JM, Bhatnagar A, Srivastava SK. Kinetic and structural characterization of the glutathione-binding site of aldose reductase. J Biol Chem. 2000;275:21587-21595.
76. Rees-Milton KJ, Jia Z, Green NC, Bhatia M, El-Kabbani O, Flynn TG. Aldehyde reductase: the role of C-terminal residues in defining substrate and cofactor specificities. Arch Biochem Biophys. 1998;355:137-144.
77. Vasiliou V, Pappa A, Petersen DR. Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. Chem Biol Interact. 2000; 129:1-19.
78. Spycher SE, Tabataba-Vakili S, O'Donnell VB, Palomba L, Azzi A. Aldose reductase induction: a novel response to oxidative stress of smooth muscle cells. FASEB J. 1997;11:181-188.
79. Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J. 1999;13:23-30.
80. Obrosova IG, Van Huysen C, Fathallah L, Cao XC, Greene DA, Stevens MJ. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J. 2002;16:123-125.
81. Lowitt S, Malone JI, Salem AF, Korthals J, Benford S. Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism. 1995;44:677-680.
82. Ho HT, Chung SK, Law JW, Ko BC, Tam SC, Brooks HL, Knepper MA, Chung SS. Aldose reductase-deficient mice develop nephrogenic diabetes insipidus. Mol Cell Biol. 2000;20:5840-5846.
83. Aida K, Ikegishi Y, Chen J, Tawata M, Ito S, Maeda S, Onaya T. Disruption of aldose reductase gene (Akr1b1) causes defect in urinary concentrating ability and divalent cation homeostasis. Biochem Biophys Res Commun. 2000;277:281-286.
84. Yamamoto M, Clark JD, Pastor JV, Gurnani P, Nandi A, Kurosu H, Miyoshi M, Ogawa Y, Castrillon DH, Rosenblatt KP, Kuro-o M. Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem. 2005;280:38029-38034.
85. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45-51.
86. Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes. 1997;46:292-300.
87. Ramasamy R, Trueblood N, Schaefer S. Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. Am J Physiol. 1998;275:H195-H203.
88. Kinoshita JH. A thirty year journey in the polyol pathway. Exp Eye Res. 1990;50:567-573.
89. Lee AY, Chung SK, Chung SS. Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc Natl Acad Sci USA. 1995;92:2780-2784.
90. Weingrad A. Discussion. Polyol pathway activity in aorta. Adv Metab Disord. 1973:2:(Suppl 2): 430-432.
91. Cheng HM, Gonzalez RG. The effect of high glucose and oxidative stress on lens metabolism, aldose reductase, and senile cataractogenesis. Metabolism. 1986;35:10-14.
92. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van den Enden M, Kilo C, Tilton RG. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 1993;42:801-813.
93. Ido Y, Chang K, Woolsey TA, Williamson JR. NADH: sensor of blood flow need in brain, muscle, and other tissues. FASEB J. 2001;15: 1419-1421.
94. Collins AR, Lyon CJ, Xia X, Liu JZ, Tangirala RK, Yin F, Boyadjian R, Bikineyeva A, Pratico D, Harrison DG, Hsueh WA. Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. Circ Res. 2009;104:e42-54.
95. Goldberg IJ, Hu Y, Noh HL, Wei J, Huggins LA, Rackmill MG, Hamai H, Reid BN, Blaner WS, Huang LS. Decreased lipoprotein clearance is responsible for increased cholesterol in LDL receptor knockout mice with streptozotocin-induced diabetes. Diabetes. 2008;57:1674-1682.
96. Taleb S, Herbin O, Ait-Oufella H, Verreth W, Gourdy P, Barateau V, Merval R, Esposito B, Clement K, Holvoet P, Tedgui A, Mallat Z. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:2691-2698.
97. Vikramadithyan RK, Hu Y, Noh HL, Liang CP, Hallam K, Tall AR, Ramasamy R, Goldberg IJ. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest. 2005; 115:2434-2443.
98. Yamaoka T, Nishimura C, Yamashita K, Itakura M, Yamada T, Fujimoto J, Kokai Y. Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia. 1995;38:255-261.
99. Wu L, Vikramadithyan R, Yu S, Pau C, Hu Y, Goldberg IJ, Dansky HM. Addition of dietary fat to cholesterol in the diets of LDL receptor knockout mice: effects on plasma insulin, lipoproteins, and atherosclerosis. J Lipid Res. 2006;47:2215-2222.
100. Noh HL, Hu Y, Park TS, DiCioccio T, Nichols AJ, Okajima K, Homma S, Goldberg IJ. Regulation of plasma fructose and mortality in mice by the aldose reductase inhibitor lidorestat. J Pharmacol Exp Ther. 2009; 328:496-503.
101. Gleissner CA, Sanders JM, Nadler J, Ley K. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:1137-1143.
102. Kaneko M, Bucciarelli L, Hwang YC, Lee L, Yan SF, Schmidt AM, Ramasamy R. Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann N Y Acad Sci. 2005;1043:702-709. (Pubitemid 41123963)
103. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces is-chemic damage to the heart. Science. 2008;321:1493-1495.
104. Srivastava S, Ramana KV, Tammali R, Srivastava SK, Bhatnagar A. Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells. Diabetes. 2006;55:901-910.
105. Ramana KV, Friedrich B, Tammali R, West MB, Bhatnagar A, Sriv-astava SK. Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. Diabetes. 2005;54:818-829.
106. Campbell M, Trimble ER. Modification of PI3K-and MAPK-dependent chemotaxis in aortic vascular smooth muscle cells by protein kinase CbetaII. Circ Res. 2005;96:197-206.
107. Ramana KV, Friedrich B, Srivastava S, Bhatnagar A, Srivastava SK. Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes. 2004; 53:2910-2920.
108. Ramana KV, Chandra D, Srivastava S, Bhatnagar A, Aggarwal BB, Srivastava SK. Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J Biol Chem. 2002;277:32063-32070.
109. Ruef J, Liu SQ, Bode C, Tocchi M, Srivastava S, Runge MS, Bhatnagar A. Involvement of aldose reductase in vascular smooth muscle cell growth and lesion formation after arterial injury. Arterioscler Thromb Vasc Biol. 2000;20:1745-1752.
110. Ramasamy R, Liu H, Oates PJ, Schaefer S. Attenuation of ischemia induced increases in sodium and calcium by the aldose reductase inhibitor zopolrestat. Cardiovasc Res. 1999;42:130-139.
111. Ananthakrishnan R, Kaneko M, Hwang YC, Quadri N, Gomez T, Li Q, Caspersen C, Ramasamy R. Aldose reductase mediates myocardial is-chemia-reperfusion injury in part by opening mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol. 2009;296:H333-H341.
112. Tracey WR, Magee WP, Ellery CA, MacAndrew JT, Smith AH, Knight DR, Oates PJ. Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury. Am J Physiol Heart Circ Physiol. 2000;279:H1447-H1452.
113. Shinmura K, Bolli R, Liu SQ, Tang XL, Kodani E, Xuan YT, Srivastava S, Bhatnagar A. Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning. Circ Res. 2002;91:240-246.
114. Kaiserova K, Tang XL, Srivastava S, Bhatnagar A. Role of nitric oxide in regulating aldose reductase activation in the ischemic heart. J Biol Chem. 2008;283:9101-9112.
115. Iwata K, Matsuno K, Nishinaka T, Persson C, Yabe-Nishimura C. Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism. J Pharmacol Sci. 2006;102:37-46.
116. Lo AC, Cheung AK, Hung VK, Yeung CM, He QY, Chiu JF, Chung SS, Chung SK. Deletion of aldose reductase leads to protection against cerebral ischemic injury. J Cereb Blood Flow Metab. 2007;27: 1496-1509.
117. Tang WH, Wu S, Wong TM, Chung SK, Chung SS. Polyol pathway mediates iron-induced oxidative injury in ischemic-reperfused rat heart. Free Radic Biol Med. 2008;45:602-610.
118. Chung SS, Ho EC, Lam KS, Chung SK. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol. 2003;14: S233-S236.
119. Ho EC, Lam KS, Chen YS, Yip JC, Arvindakshan M, Yamagishi S, Yagihashi S, Oates PJ, Ellery CA, Chung SS, Chung SK. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes. 2006;55:1946-1953.
120. Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, Stevens MJ. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes. 2003;52:864-871.
121. Li Q, Hwang YC, Ananthakrishnan R, Oates PJ, Guberski D, Ramasamy R. Polyol pathway and modulation of ischemia-reperfusion injury in Type 2 diabetic BBZ rat hearts. Cardiovasc Diabetol. 2008;7:33.
122. Srivastava S, Chandrasekar B, Bhatnagar A, Prabhu SD. Lipid peroxidation-derived aldehydes and oxidative stress in the failing heart: role of aldose reductase. Am J Physiol Heart Circ Physiol. 2002;283: H2612-H2619.
123. Yang J, Moravec CS, Sussman MA, DiPaola NR, Fu D, Hawthorn L, Mitchell CA, Young JB, Francis GS, McCarthy PM, Bond M. Decreased SLIM1 expression and increased gelsolin expression in failing human hearts measured by high-density oligonucleotide arrays. Circulation. 2000;102:3046-3052.
124. Mylari BL, Beyer TA, Siegel TW. A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners. J Med Chem. 1991;34:1011-1018.
125. Sarges R, Oates PJ. Aldose reductase inhibitors: recent developments. Prog Drug Res. 1993;40:99-161.
126. Alexiou P, Pegklidou K, Chatzopoulou M, Nicolaou I, Demopoulos VJ. Aldose reductase enzyme and its implication to major health problems of the 21(st) century. Curr Med Chem. 2009;16:734-752.
127. Johnson BF, Nesto RW, Pfeifer MA, Slater WR, Vinik AI, Chyun DA, Law G, Wackers FJ, Young LH. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. Diabetes Care. 2004;27:448-454.
128. Didangelos TP, Athyros VG, Karamitsos DT, Papageorgiou AA, Kour-toglou GI, Kontopoulos AG. Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy. Clin Drug Investig. 1998;15:111-121.
129. Bank N, Mower P, Aynedjian HS, Wilkes BM, Silverman S. Sorbinil prevents glomerular hyperperfusion in diabetic rats. Am J Physiol. 1989; 256:F1000-F1006.
130. Tilton RG, Baier LD, Harlow JE, Smith SR, Ostrow E, Williamson JR. Diabetes-induced glomerular dysfunction: links to a more reduced cytosolic ratio of NADH/NAD +. Kidney Int. 1992;41:778-788.
131. Beyer-Mears A, Murray FT, Cruz E, Rountree J, Sciadini M. Comparison of sorbinil and ponalrestat (Statil) diminution of proteinuria in the BB rat. Pharmacology. 1992;45:285-291.
132. Itagaki I, Shimizu K, Kamanaka Y, Ebata K, Kikkawa R, Haneda M, Shigeta Y. The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats. Diabetes Res Clin Pract. 1994;25:147-154.
133. Donnelly SM, Zhou XP, Huang JT, Whiteside CI. Prevention of early glomerulopathy with tolrestat in the streptozotocin-induced diabetic rat. Biochem Cell Biol. 1996;74:355-362.
134. Keogh RJ, Dunlop ME, Larkins RG. Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation. Metabolism. 1997;46:41-47.
135. Dan Q, Wong RL, Yin S, Chung SK, Chung SS, Lam KS. Interaction between the polyol pathway and non-enzymatic glycation on mesangial cell gene expression. Nephron Exp Nephrol. 2004;98:e89-e99.
136. Passariello N, Sepe J, Marrazzo G, De Cicco A, Peluso A, Pisano MC, Sgambato S, Tesauro P, D'Onofrio F. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Diabetes Care. 1993; 16:789-795.
137. Iso K, Tada H, Kuboki K, Inokuchi T. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001;15:241-244.
138. Oates PJ, Klioze SS, Schwarts PF, Boland AD, Group TZDNS. Aldose reductase inhibitor zopolrestat reduces elevated urinary albumin excretion rate in type 1 diabetes mellitus subjects with incipient diabetic nephropathy. J Am Soc Nephrol. 2008;19:642A.